Toronto, Ontario – TheNewswire – May 28, 2025 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) is pleased to announce its participation in the 58th Annual Meeting of the Association for European Paediatric and Congenital Cardiology (AEPC) being held on May 28th-31st 2025 in Hamburg, Germany.

 

The AEPC is a network of specialists committed to the practice and advancement of Congential Cardiology and closely related fields. Since its founding in 1963 AEPC has grown to become the largest global association in congenital cardiology with over 1,000 members. We are excited to be part of this international community and to work with its members to enhance cardiac care.

 

This year’s meeting is hosted by the local organising committee from the University Heart & Vascular Center Hamburg, Children’s Heart Medicine and Adults with Congenital Heart Disease. Ventripoint is exhibiting at the meeting and we look forward to seeing our customers, connecting with  clinicians within the international congenital cardiology community and continuing to expand our global network.

 

Our focus for this year is on growing our customer base and working with clinicians to expand the use of VMS+ in routine clinical workflow. The advancements provided in VMS+ versions 3.2 and 4.0 during the past year were designed to provide improved product-user fit and better integration into clinical workflow.  VMS+ enables a more efficient patient journey by providing information about the structure and function of the heart with accuracy equivalent to cardiac MRI at the time of the patient’s first echo scan. This detailed information, generated early in the care journey, leads to improved quality of diagnosis, potentially shortening time to therapy, and increased efficacy of patient management and care throughout the patient’s life.

 

“We value the opportunity to support AEPC, its members within 32 European countries and their peers from other continents” said Ventripoint President and CEO Hugh MacNaught, “VMS+ provides the ability to deliver fast, affordable and accessible volumetric assessments of cardiac function throughout a patient’s life journey with accuracy comparable to cardiac MRI.”

 

In other news:

 

The Company also announces it has postponed its annual meeting of shareholders as a result of the strike notice issued by Canadian postal workers union on May 19, 2025. The Company had scheduled the annual shareholders meeting for July 2, 2025 but is concerned that its registrar and transfer agent may be prevented from mailing the meeting materials to shareholders on a timely basis in the event of a postal strike. The Company will re-schedule the annual meeting of shareholders upon resolution of the possible postal strike actions.

 

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

 

For further information, please contact:

 

Hugh MacNaught

hmacnaught@ventripoint.com

(604) 671-4201

 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

 

About Ventripoint Diagnostics Ltd.

 

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

  

Forward Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends'' and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to several factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether because of new information, future events or otherwise, unless so required by applicable securities laws.